EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering

EyePoint Pharmaceuticals (EYPT) Prices 9.1M Share Common Offering at $11/Sh

February 2, 2021 5:48 AM EST

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public... More

Pre-Open Stock Movers 01/28: (KOSS) (HIMS) (EYPT) Higher; (AMC) (BBY) (NOK) (EXPR) Lower (more...)

January 28, 2021 9:29 AM EST

Pre-pen Stock Movers

Koss Corporation (NASDAQ: KOSS) 78% HIGHER; adds to recent short-squeeze gains.

AMC Entertainment Holdings, Inc. (NYSE: AMC) 35.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze. Trading firms restrict trading.

Him & Hers Health (NYSE:... More

EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD

January 28, 2021 7:10 AM EST

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).

EYP-1901 leverages the Companys proprietary Durasert® drug delivery technology that has been used in four FDA-approved products, including EyePoints YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. EYP-1901 uses a bioerodible Durasert formulation combined with a clinically validated anti-VEGF molecule, vorolanib. In oral formulation, vorolanib demonstrated efficacy and... More